Country sequencing, vendor geography, and QP release chains are strategic decisions made, well or poorly, at the US IND stage, long before a company believes it is ready to think globally.
White Paper
Designing a Global IND Strategy Before You Think You Need One
Related Resources
All Resources
post
Regulatory Affairs Compliance Strategies
Read More
post
The FDA NDA Review Timeline Explained: A Step-by-Step Breakdown
Read More
post
Project Orbis: Accelerating Global Access to Innovative Cancer Therapies
Read More
post
The Importance of Quality in Drug Development with Insights from the FDA Fiscal Year 2023 Report on the State of Pharmaceutical Quality
Read More
Let's move from science to success.
Let’s Talk